4DMedical Lands GSK Deal and UK Clearance as CT:VQ™ Expands Globally

Pharma Partnership Boosts 4DMedical’s Clinical Footprint

4DMedical (ASX:4DX) has inked a one-year contract with GlaxoSmithKline (GSK) to supply its advanced lung imaging analytics for pulmonary drug development. Starting 1 May 2026, this collaboration leverages 4DMedical’s proprietary software to provide sensitive, quantitative lung biomarkers that can improve clinical trial efficiency and patient stratification. While the contract’s financial details remain confidential and individually immaterial, the deal signals growing confidence from global biopharmaceutical leaders in 4DMedical’s platform, which already counts AstraZeneca among its partners.

UK Market Access Opens with CT:VQ™ Clearance

Following its CE Mark certification in March 2026, 4DMedical’s CT:VQ™ lung imaging solution has now secured UKCA certification, allowing immediate clinical use across public and private healthcare providers in the United Kingdom. The UK’s diagnostic imaging environment is one of the world’s most sophisticated, with millions of chest CT scans performed annually for conditions ranging from lung cancer to pulmonary embolism. CT:VQ™’s ability to deliver quantitative ventilation and perfusion data from routine non-contrast CT scans positions it as a disruptive alternative to traditional nuclear medicine approaches.

This UK clearance complements the company’s existing FDA approval and European CE Mark, giving 4DMedical regulatory clearance for CT:VQ™ across major Western markets including the US, EU, Canada, and New Zealand. The company’s ongoing clinical research at renowned institutions like London’s Royal Brompton Hospital further cements its credibility in cardiopulmonary imaging.

Advances in Coronary Calcium Analysis and US Reimbursement

4DMedical also announced regulatory clearance from Health Canada for its Coronary Artery Calcium (CAC) analysis software, coinciding with its presence at the Canadian Association of Radiologists Annual Scientific Meeting. Meanwhile, in the US, the Centers for Medicare & Medicaid Services (CMS) has established a new reimbursement code (HCPCS G0680) for AI-based opportunistic CAC analysis from routine chest CT scans, reimbursing providers US$15.50 per study. This reimbursement pathway is a critical enabler for broader clinical adoption, removing the need for dedicated cardiac CT imaging and additional scan time.

ASX 200 Inclusion Reflects Growing Market Confidence

Effective 20 April 2026, 4DMedical has been included in the S&P/ASX 200 Index, Australia’s premier benchmark representing the top 200 companies by market capitalisation. This inclusion broadens its institutional shareholder base and increases visibility among index-tracking funds. The move follows a series of milestones including FDA clearance of CT:VQ™, deployments at six leading US academic medical centres such as Stanford and Mayo Clinic, and the Philips distribution agreement. The company’s recent CE Mark certification and $83 million capital raise have underpinned this momentum.

CEO Andreas Fouras highlighted the strategic value of the GSK partnership and UK market entry, noting the platform’s expanding role in pharmaceutical development and clinical care. He also pointed to a deepening commercial pipeline, hinting at further updates ahead.